Browse the evidence

GLP-1 receptor agonists (semaglutide, tirzepatide) produce modest weight loss (2.3–5%) in breast cancer patients, which is significantly attenuated compared to non-cancer populations, likely due to concurrent endocrine therapy.

If you have breast cancer and are taking hormone-blocking therapy, GLP-1 drugs like semaglutide will likely help you lose some weight, but not as much as they do for people without cancer. Expect a modest loss (around 2-5%) rather than dramatic results. This is likely because your cancer treatment changes your metabolism. It appears safe regarding cancer recurrence, but discuss timing with your oncologist.

GLP-1 receptor agonist use in breast cancer patients does not increase the risk of cancer recurrence and may reduce cardiovascular morbidity.

For breast cancer patients, GLP-1 drugs appear safe regarding cancer recurrence. They may also offer significant cardiovascular protection, which is valuable since some cancer treatments can stress the heart. This benefit exists independently of weight loss.

Sympathomimetic agents (phentermine, phentermine/topiramate, naltrexone/bupropion) cause mild gastrointestinal side effects (constipation, dry mouth, nausea) with lower discontinuation rates compared to GLP-1 agonists.

If you take a sympathomimetic medication like phentermine or naltrexone/bupropion, you may experience mild side effects like constipation or dry mouth. These are generally less severe than the GI side effects associated with GLP-1 agonists. Stay hydrated and monitor your symptoms.

The cardiometabolic benefits of exercise, particularly on glucose regulation and inflammation, may be attenuated or dependent on weight loss in individuals with obesity.

Be aware that while exercise is beneficial, achieving weight loss may be necessary to fully improve glucose regulation and inflammation in obesity. However, do not stop exercising if weight loss is difficult; other benefits remain.

Carbohydrate-modified diets (low glycemic load, high fiber, or reduced-CHO) are more effective for weight loss or weight regain prevention in individuals with impaired glucose metabolism (prediabetes, IFG, or IGT) compared to those with normal glucose tolerance, supporting the hypothesis of precision nutrition based on glycemic status.

If you have prediabetes or impaired glucose tolerance, you may lose more weight or prevent weight regain by choosing a carbohydrate-modified diet (such as low glycemic load, high fiber, or reduced carbohydrate) compared to a standard high-carbohydrate diet. While the evidence is not yet definitive, this approach aligns with your body's likely insulin resistance. Consult a healthcare provider for testing and personalized guidance.

Women with type 2 diabetes treated with GLP-1 receptor agonists achieve significantly greater weight loss than men after 12 months, despite similar glycemic control improvements.

If you are a woman with Type 2 Diabetes on a GLP-1 agonist, you are statistically more likely to achieve significant weight loss (over 5% or 10%) than a man on the same medication class, particularly after 6-12 months. This does not mean men won't lose weight, but the magnitude of benefit tends to be greater in women. Glycemic control (HbA1c) improves similarly for both sexes.

Glucagon receptor (GCGR) agonism increases energy expenditure and promotes weight loss, particularly when combined with GLP-1R and/or GIPR agonism in dual or triple receptor agonists.

Current obesity treatments often lead to weight regain because they don't significantly increase energy expenditure. New drugs that activate the glucagon receptor (GCGR), either alone or combined with GLP-1/GIP drugs, are designed to boost energy expenditure and prevent this metabolic slowdown. While early results show significant weight loss (up to 24% in some trials), long-term clinical data is still emerging, and these are prescription medications requiring medical supervision.

In a mixed population of diabetic and non-diabetic patients, liraglutide (up to 3 mg) and semaglutide (up to 1 mg) produce statistically equivalent weight loss, contradicting findings from trials using higher doses or specific diabetic cohorts.

If you are using liraglutide or semaglutide at lower, standard starting-to-maintenance doses (up to 3mg and 1mg respectively), expect similar weight loss results. The perceived superiority of semaglutide in marketing often relies on higher doses (2.4mg) not used in this study. Focus on adherence and titration rather than switching solely for weight loss efficacy at these doses.

Higher baseline BMI and the presence of symptomatic comorbidities (specifically knee osteoarthritis or obstructive sleep apnoea) are associated with greater improvements in health utility scores following semaglutide 2.4 mg treatment.

If you have a higher BMI (over 35 or 40) and suffer from knee osteoarthritis or sleep apnea, semaglutide 2.4 mg once weekly may offer even greater improvements in your daily health quality of life than it would for someone with a lower BMI or fewer comorbidities.

Tirzepatide-supported digital weight loss programs achieve high mean weight loss (13.8% over 16 weeks) and high engagement rates, but proactive coaching messaging does not significantly improve weight loss outcomes compared to reactive or control models.

Tirzepatide delivers substantial weight loss (approx 14% in 16 weeks) even with minimal coaching interaction. You do not need to send frequent messages to your coach to lose weight; the medication is the primary driver. Focus on adherence to the dosing schedule and monitoring for side effects rather than trying to maximize engagement metrics.

Shortened sleep duration (40% reduction for 4 nights) impairs adrenergic stimulation of lipolysis in postmenopausal women, reducing lipid efflux and potentially promoting abdominal adiposity independent of caloric intake.

If you are a postmenopausal woman struggling with abdominal fat despite diet and exercise, check your sleep. This research shows that even short-term sleep restriction (reducing sleep by 40% for just 4 nights) blunts your body's ability to break down fat (lipolysis). Prioritizing adequate sleep duration is a critical, often overlooked lever for managing abdominal adiposity in this demographic.

Myostatin and activin A inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) combined with GLP-1 agonists can increase lean mass and reduce fat mass more effectively than GLP-1 agonists alone.

New drugs targeting myostatin (like bimagrumab) are being tested alongside GLP-1s to build muscle while losing fat. These are currently in clinical trials and not yet widely available.

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.

Tirzepatide (2.5 mg weekly) significantly improves glycemic control and reduces body weight in patients with type 2 diabetes during Ramadan fasting, with a favorable safety profile characterized by mild gastrointestinal side effects and no reported hypoglycemia.

If you have type 2 diabetes and plan to fast during Ramadan, tirzepatide (2.5 mg weekly) can help improve your blood sugar and weight without causing low blood sugar. You might experience mild stomach issues like nausea, but these are usually manageable and do not require stopping the medication or breaking your fast. Consult your doctor to ensure it fits your overall treatment plan.

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.

Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.

Tirzepatide is a broadly acceptable and preferred long-term treatment for comorbid obesity and obstructive sleep apnea (COBOSA) by patients, offering efficacy comparable to CPAP with different adherence profiles.

If you have obesity and sleep apnea, tirzepatide is a valid, once-weekly treatment option that many patients prefer over CPAP. Discuss with your doctor if it's right for you, considering factors like cost, side effects, and your preference for injections vs. devices.

Reallocating 30 minutes of daily sedentary time to moderate-to-vigorous physical activity (MVPA) in young, healthy, active adults increases daily energy intake by approximately 113–120 kcal and alters appetite hormones (higher fasting ghrelin, lower postprandial PYY) to compensate for energy expenditure, without affecting hedonic food reward traits.

If you are already active and healthy, increasing your moderate-to-vigorous exercise by 30 minutes a day will likely make you hungrier and cause you to eat about 120 more calories. This is your body's natural way of balancing energy. To manage weight, you must consciously account for this increased intake rather than assuming exercise alone creates a deficit. If your goal is performance, use this hunger to fuel your activity.

GLP-1 receptor agonist use during radiation therapy causes rapid weight loss and anatomic changes that compromise immobilization reproducibility and dosimetric accuracy, necessitating adaptive radiotherapy or temporary holding of the medication.

If you are taking GLP-1 drugs (like Ozempic or Wegovy) while getting radiation, tell your radiation team immediately. These drugs cause weight loss and stomach changes that can make your radiation treatment less accurate. Your team may ask you to pause the drug or scan you more often to adjust the treatment plan. This is to keep you safe and ensure the radiation hits the tumor correctly.

Dose de-escalation (tapering) or low-dose maintenance therapy may modestly limit the rate and magnitude of weight regain compared to abrupt cessation, but robust randomized evidence is currently lacking.

If you want to stop your incretin medication, talk to your doctor about tapering the dose or extending the time between injections rather than stopping abruptly. While this might help slow down weight regain, it is not a guaranteed solution, and you should expect some regain. Continuing at a lower dose is generally better than stopping completely.

Nutrient-stimulated hormone (NuSH) therapies, including GLP-1 and dual/tri-agonists, produce significant weight loss and cardiometabolic improvements in real-world settings, though response heterogeneity, high discontinuation rates, and post-cessation weight regain remain unresolved challenges.

NuSH therapies (like semaglutide or tirzepatide) are highly effective for significant weight loss and metabolic health in real-world use, but they are not magic bullets. Expect a significant portion of people to not respond well, experience side effects leading to stopping the drug, or regain weight after stopping. Success requires individualized dosing, lifestyle support, and an understanding that obesity management is often a long-term commitment rather than a quick fix.

β-hydroxy-β-methylbutyrate (HMB, 3 g/day) has conditional utility for muscle hypertrophy, showing benefits primarily during high training stress or caloric deficits, but is largely neutral in well-fed, resistance-trained individuals.

If you are dieting or doing extremely high-volume training, 3g of HMB daily might help preserve muscle. If you are eating well and training normally, HMB is likely a waste of money as it shows no benefit in this group.

GLP-1 receptor agonists (GLP-1RAs), such as semaglutide, reduce 'food noise' (heightened, persistent food cue reactivity and food-related intrusive thoughts), which contributes to reduced energy intake and weight loss.

If you struggle with constant thoughts about food ('food noise') that make dieting hard, GLP-1 medications like semaglutide may help quiet those thoughts. This isn't just about feeling full; it's about reducing the mental obsession with food. Talk to your doctor about whether this medication is right for you, especially if you have a history of depression, as monitoring is important.